Related Experiment Video
Updated: Apr 6, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development
A M Roncero1,2, P López-Nieva1,2, M A Cobos-Fernández1,2,3
1Centro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas- Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Abstract:
The JAK-STAT pathway has a substantial role in lymphoid precursor cell proliferation, survival and differentiation. Nonetheless, the contribution of JAK2 to T-cell lymphoblastic lymphoma (T-LBL) development remains poorly understood. We have identified one activating TEL-JAK2 translocation and four missense mutations accumulated in 2 out of 16 T-LBL samples. Two of them are novel JAK2 mutations and the other two are reported for the first time in T-LBL. Notably, R683G and I682T might have arisen owing to RNA editing. Mutated samples showed different mutated transcripts suggesting sub-clonal heterogeneity. Functional approaches revealed that two JAK2 mutations (H574R and R683G) constitutively activate JAK-STAT signaling in γ2A cells and can drive the proliferation of BaF3-EpoR cytokine-dependent cell line. In addition, aberrant hypermethylation of SOCS3 might contribute to enhance the activation of JAK-STAT signaling. Of utmost interest is that primary T-LBL samples harboring JAK2 mutations exhibited increased expression of LMO2, suggesting a mechanistic link between JAK2 mutations and the expression of LMO2, which was confirmed for the four missense mutations in transfected γ2A cells. We therefore propose that active JAK2 contribute to T-LBL development by two different mechanisms, and that the use of pan-JAK inhibitors in combination with epigenetic drugs should be considered in future treatments.
Insights
Activating mutations in JAK2 were found in T-cell lymphoblastic lymphoma (T-LBL), promoting cancer cell growth. These JAK2 mutations may be targeted with pan-JAK inhibitors and epigenetic drugs for T-LBL treatment.
Area of Science:
- Oncology
- Molecular Biology
- Signal Transduction
Background:
- The Janus kinase-Signal transducer and activator of transcription (JAK-STAT) pathway is crucial for lymphoid cell development.
- The specific role of JAK2 in T-cell lymphoblastic lymphoma (T-LBL) pathogenesis is not well understood.
Purpose of the Study:
- To investigate the involvement of JAK2 mutations and alterations in T-cell lymphoblastic lymphoma (T-LBL).
- To explore the functional consequences of identified JAK2 mutations on cellular signaling and oncogenesis.
Main Methods:
- Screening of T-LBL samples for JAK2 mutations and translocations.
- Functional assays using cell lines (γ2A, BaF3-EpoR) to assess the impact of JAK2 mutations on signaling pathways.
- Analysis of SOCS3 methylation and LMO2 expression in T-LBL samples and transfected cells.
Main Results:
- Identified one TEL-JAK2 translocation and four missense JAK2 mutations in T-LBL samples, including novel mutations.
- Demonstrated that specific JAK2 mutations (H574R, R683G) constitutively activate JAK-STAT signaling and promote cell proliferation.
- Observed increased LMO2 expression in T-LBL samples with JAK2 mutations, suggesting a mechanistic link.
Conclusions:
- Active JAK2, through mutations or translocations, contributes to T-cell lymphoblastic lymphoma (T-LBL) development.
- Aberrant SOCS3 methylation may further enhance JAK-STAT signaling activation.
- Combination therapy with pan-JAK inhibitors and epigenetic drugs warrants consideration for T-LBL treatment.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
02:21Cancers Originate from Somatic Mutations in a Single Cell